Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Jame Abraham,Albert J. Montero,Rachel C. Jankowitz,Mohamad Adham Salkeni,Jan H. Beumer,Brian F. Kiesel,Fanny Piette,Laura M. Adamson,Rebecca J. Nagy,Richard B. Lanman,Jeff Sperinde,Weidong Huang,Carmen J. Allegra,Ashok Srinivasan,Ying Wang,Katherine L. Pogue-Geile,Peter C. Lucas,Samuel A. Jacobs

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

2019

Jame Abraham
Albert J. Montero
Rachel C. Jankowitz
Mohamad Adham Salkeni
Jan H. Beumer
Brian F. Kiesel
Fanny Piette
Laura M. Adamson
Rebecca J. Nagy
Richard B. Lanman
Jeff Sperinde
Weidong Huang
Carmen J. Allegra
Ashok Srinivasan
Ying Wang
Katherine L. Pogue-Geile
Peter C. Lucas
Samuel A. Jacobs

PURPOSEPatients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mecha...

Keywords:

Internal medicine
Neratinib
HER2 Positive Breast Cancer
Oncology
Pathology
Human Epidermal Growth Factor Receptor 2
Trastuzumab
Medicine
Pertuzumab
Metastatic breast cancer
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations